The Biogen Canada team proudly shared with Canadians important results from the NURTURE clinical trial published in Neuromuscular Disorders. A press release issued on the Canadian newswire included reaction from the SMA community underscoring the critical need for newborn screening for SMA across the country.

There is also good news for patient access to SPINRAZA™ in Canada in Maritime province of Nova Scotia which has now joined several other provinces to have expanded access. The Canadian team is committed to ensuring SMA patients across Canada have equal access to the best possible care and will continue their work to ensure the remaining provinces: British Columbia, Manitoba, Prince Edward Island and Newfoundland & Labrador will soon follow suit.

The Ontario government expands coverage for SPINRAZA™.

Saskatchewan has become the second province in Canada to grant broad access to SPINRAZA™ for SMA patients.

This is an important milestone for the SMA community and allows more patients in Alberta who have been diagnosed with this rare condition to be eligible for reimbursement.